Secukinumab — Membership Pricing

Other medications in Rheumatology

• Tocilizumab
• Tofacitinib
• Upadacitinib
• Voclosporin
• Abatacept
• Anakinra
• Anifrolumab
• Baricitinib

About Secukinumab

Secukinumab is a biologic medication offering significant relief for chronic inflammatory conditions like psoriasis and arthritis. If you're managing one of these conditions, understanding your treatment options and costs is crucial. TheDrugClub helps members navigate these challenges, potentially offering substantial savings on medications like secukinumab to make your health journey more affordable.

What is Secukinumab and What Does It Treat?

Secukinumab is a type of biologic medication known as a monoclonal antibody. It's prescribed to treat several chronic inflammatory and autoimmune conditions. These include moderate to severe plaque psoriasis in adults and children, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa. For individuals living with these conditions, secukinumab can significantly reduce symptoms, improve quality of life, and prevent further disease progression.

How Does Secukinumab Work?

Secukinumab works by specifically targeting and blocking a protein in the body called interleukin-17A (IL-17A). IL-17A is a key cytokine, or signaling protein, that plays a crucial role in the inflammation associated with the conditions secukinumab treats. By neutralizing IL-17A, secukinumab helps to reduce the inflammatory response, thereby alleviating symptoms like skin plaques, joint pain, stiffness, and skin lesions. This targeted approach helps to minimize effects on other parts of the immune system.

Typical Costs of Secukinumab

As a specialty biologic medication, secukinumab typically comes with a high price tag. Without insurance or significant discounts, a single dose or monthly supply can cost thousands of dollars. The exact cost can vary widely based on factors such as your insurance coverage, prescribed dosage, the pharmacy you use, and your geographic location. Managing these expenses can be a significant concern for many patients, highlighting the importance of exploring all available savings options.

How TheDrugClub Can Help Members Save

TheDrugClub aims to make essential medications like secukinumab more accessible and affordable for our members. We understand the financial burden that specialty medications can

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Secukinumab is approved for (FDA label)

COSENTYX is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. ( 1.2 ) active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older. ( 1.3 ) active non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation. ( 1.4 ) active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older. ( 1.5 ) moderate to severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older. ( 1.6 ) 1.1 Plaque Psoriasis COSENTYX ® is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. 1.3 Ankylosing Spondylitis COSENTYX is indicated for the treatment of active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older. 1.4 Non-Radiographic Axial Spondyloarthritis COSENTYX is indicated for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation. 1.5 Enthesitis-Related Arthritis COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older. 1.6 Hidradenitis Suppurativa COSENTYX is indicated for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older.

Source: Read the full FDA label on DailyMed. Label effective date: August 25, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Secukinumab (FDA label)

Injection for subcutaneous use: 300 mg/2 mL as a clear to opalescent, colorless to slightly yellowish solution in a single-dose UnoReady pen 150 mg/mL as a clear to opalescent, colorless to slightly yellowish solution in a single-dose Sensoready pen 150 mg/mL as a clear to opalescent, colorless to slightly yellowish solution in a single-dose prefilled syringe 75 mg/0.5 mL as a clear to opalescent, colorless to slightly yellowish solution in a single-dose prefilled syringe (for pediatric patients less than 50 kg) Injection for intravenous use: 125 mg/5 mL as a clear to opalescent, colorless to slightly yellowish solution in a single-dose vial for dilution prior to intravenous infusion (for healthcare professional use only).

Source: FDA prescribing information (DailyMed). Set ID: 77c4b13e-7df3-42d4-81db-3d0cddb7f67a. SPL document ID: 53e23ae2-ecfb-4322-8e42-cc9a2d71bcb9. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Secukinumab (FDA label)

The following adverse reactions are discussed in greater detail elsewhere in the labeling: Infections [see Warnings and Precautions (5.1)] Hypersensitivity Reactions [see Warnings and Precautions (5.2)] Inflammatory Bowel Disease [see Warnings and Precautions (5.4)] Eczematous Eruptions [see Warnings and Precautions (5.5)] Most common adverse reactions (> 1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 77c4b13e-7df3-42d4-81db-3d0cddb7f67a. SPL document ID: 53e23ae2-ecfb-4322-8e42-cc9a2d71bcb9. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Secukinumab (FDA label)

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis and angioedema have been reported during treatment with COSENTYX [see Warnings and Precautions (5.2)] . Serious hypersensitivity to secukinumab or any excipients in COSENTYX. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 77c4b13e-7df3-42d4-81db-3d0cddb7f67a. SPL document ID: 53e23ae2-ecfb-4322-8e42-cc9a2d71bcb9. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Secukinumab (FDA label)

Infections : Serious infections have occurred. Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue COSENTYX until the infection resolves. ( 5.1 ) Hypersensitivity Reactions : If an anaphylactic reaction or other serious allergic reaction occurs, discontinue COSENTYX immediately and initiate appropriate therapy. ( 5.2 ) Tuberculosis (TB) : Prior to initiating treatment with COSENTYX, evaluate for TB. ( 5.3 ) Inflammatory Bowel Disease (IBD) : Cases of IBD were observed in clinical trials. Exercise caution when prescribing COSENTYX to patients with IBD. ( 5.4 ) Eczematous Eruptions : Cases of severe eczematous eruptions have occurred in patients receiving COSENTYX. ( 5.5 ) Immunizations : Avoid use of live vaccines in patients treated with COSENTYX. ( 5.7 ) 5.1 Infections COSENTYX may increase the risk of infections.

Source: FDA prescribing information (DailyMed). Set ID: 77c4b13e-7df3-42d4-81db-3d0cddb7f67a. SPL document ID: 53e23ae2-ecfb-4322-8e42-cc9a2d71bcb9. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Secukinumab (FDA label)

Certain CYP450 Substrates Increased concentrations of cytokines (e.g., IL-17) during chronic inflammation associated with certain diseases including PsO, PsA, AS, nr-axSpA, ERA, and HS may suppress the formation of CYP enzymes. Upon initiation or discontinuation of COSENTYX in patients who are receiving concomitant CYP450 substrates, particularly those where minimal decreases in the concentration may reduce CYP substrate effectiveness or minimal increases in the concentration may increase CYP substrate adverse reactions, consider monitoring for therapeutic effect or concentration of the CYP substrate and consider dosage adjustment of the CYP substrate as needed [see Clinical Pharmacology (12.3)] .

Source: FDA prescribing information (DailyMed). Set ID: 77c4b13e-7df3-42d4-81db-3d0cddb7f67a. SPL document ID: 53e23ae2-ecfb-4322-8e42-cc9a2d71bcb9. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.